Today I think we’re going to clearly outline to you, how we believe this, by this time next year. we will be the clear leader in non-invasive body contouring. we have all the elements in place to execute on this plan as well as the fact that our performance continues to improve and we continue to outpace the competition.The EDU today will spend time discussing the many baskets of the EDU and the significant growth opportunity that it represents. And I would like to say that I expect by the end of the day today to have our most of the questions answered, and to have some new thinking around the growth prospects of Syneron and how I believe that we’re tremendously undervalued and probably the company to invest in our space. So I would like to introduce Dr. Alan Gold for his presentation on cardio aesthetic practices, Dr. Gold? Alan Gold Good morning, I’m going to present a little bit of a different perspective, if you notice there isn’t anything in my presentation as of listed that’s going to be scientifically based. When I spoke with Lou about the investor meeting coming up, I thought it might of interest to be able to present from a different point of view. How I look at Syneron and you’ve seen some of the credential before, this is not appropriate, I just want to give an idea of what my understanding of the market is based up on. I’ve been the President of the most of the National Plastic Surgery societies over the years. I’m Chairman now the Industry Relation Task Force of the American Society for Aesthetic Plastic Surgery. Why is that important? It’s important because it allows me to understand the working of some of our industry partners amongst them Syneron and Candela.